Hikma Pharmaceuticals (LON:HIK) Insider Tobias Hestler Acquires 7,500 Shares of Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was bought at an average price of GBX 1,648 per share, with a total value of £123,600.

Hikma Pharmaceuticals Stock Down 1.7%

Shares of LON HIK opened at GBX 1,621.18 on Tuesday. Hikma Pharmaceuticals PLC has a 52 week low of GBX 1,187 and a 52 week high of GBX 1,865. The business has a 50-day simple moving average of GBX 1,538.45 and a two-hundred day simple moving average of GBX 1,453.55. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The company has a market cap of £3.39 billion, a P/E ratio of 8.96, a P/E/G ratio of 2.38 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HIK. Citigroup reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday, July 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday. Berenberg Bank restated a “buy” rating and issued a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Finally, Jefferies Financial Group lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average target price of GBX 2,038.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.